{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Aprea Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"APRE"},"Address":{"label":"Address","value":"535 BOYLSTON STREET, BOSTON, Massachusetts, 2116, United States"},"Phone":{"label":"Phone","value":"+1 617 463-9385"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML)."},"CompanyUrl":{"label":"Company Url","value":"https://www.aprea.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Lars AbrahmsTn","title":"Chief Scientific Officer &amp; Senior Vice President"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}